Ibrahim Aldoss, MD, associate professor, City of Hope, explores recent findings on ponatinib as a first-line treatment for Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).

The new collaborations with Tracer Biotechnologies and Foresight Diagnostics expand QIAGEN’s reach in MRD testing and cover solid tumors and hematological cancers. Minimal residual disease (MRD ...

FN America recently discovered a condition on the FN Reflex MRD pistol that, in very limited circumstances when using the incorrect set of screws to mount specific optics, the pistol could ...

Key findings include: Personalized whole-genome sequencing (WGS) panels utilizing up to 1,000 somatic variants were successfully created via Precise MRD for 97.3% of patients tested. Precise MRD ...

This landmark event marked a significant milestone in advancing precision oncology, fostering collaboration, and driving innovation in the fields of circulating tumor DNA (ctDNA), Molecular Residual ...

5 sensitivity. Over 50 percent of patients achieved sustained MRD negativity for at least 24 months, and more than two-thirds maintained MRD negativity at 12 months. This translated to a ...

30 scientific abstracts will be presented using clonoSEQ for MRD assessment across multiple types of blood cancers SEATTLE, May 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ...

(RTTNews) - Natera, Inc. (NTRA), a leader in cell-free DNA and precision medicine, announced that its genome-based Signatera MRD assay has secured Medicare coverage under LCD L38779. This coverage ...

We know if we test for minimal residual disease [MRD] using a circulating-tumor DNA test called PhasED-Seq [phased variant enrichment and detection sequencing], that if that test is positive ...

to co-develop and commercialize minimal residual disease (MRD) assays for solid tumors on QIAGEN’s QIAcuity digital PCR platform.